PT - JOURNAL ARTICLE AU - Jacob G. Scott AU - Geoffrey Sedor AU - Patrick Ellsworth AU - Jessica A. Scarborough AU - Kamran Ahmed AU - Steven A. Eschrich AU - Javier F. Torres-Roca AU - Michael W. Kattan TI - GARD is a pan-cancer predictor of clinical outcome in radiation treated patients AID - 10.1101/2020.12.19.20248484 DP - 2021 Jan 01 TA - medRxiv PG - 2020.12.19.20248484 4099 - http://medrxiv.org/content/early/2021/03/27/2020.12.19.20248484.short 4100 - http://medrxiv.org/content/early/2021/03/27/2020.12.19.20248484.full AB - Purpose/Objectives Despite advances in cancer genomics, radiation therapy (RT) is still prescribed based on an empiric one-size-fits-all paradigm. Previously, we proposed a novel algorithm using the genomic adjusted radiation dose (GARD) to personalize RT prescription dose based on the biological effect of a given physical RT dose, calculated using individual tumor genomics – hypothesizing that the extra genomic dimension would reveal differences in clinical outcome not apparent with standard physical RT dose alone. To test this hypothesis, and the GARD-based RT dosing paradigm, we performed a pooled pan-cancer analysis in 9 separate clinical cohorts of 1,574 unique patients that represent all available cohorts with the data required to calculate GARD, together with clinical outcome.Materials/Methods We collected 9 previously-published datasets for which all information to calculate GARD was available. Two clinical endpoints were defined: (i) time to first recurrence and (ii) overall survival. The recurrence and survival analysis included a total of 1,257 (972 +RT, 285 -RT) and 636 patients (414 +RT, 222 -RT), respectively. A stratified Cox proportional hazard regression analysis model was constructed for each disease site and each outcome using GARD as the covariate, and a common GARD effect was estimated. Secondary Cox models were constructed similarly using total RT dose and sham-GARD (for -RT patients) as the covariates for comparison. Restricted cubic splines with 3-5 knots were included to allow for possible nonlinear associations. Interaction tests between GARD and whether patients received RT were performed using the Wald statistic for all cohorts.Results Pooled analysis of all available data reveal that GARD is a continuous predictor of recurrence (HR = 0.984, CI [0.982, 0.996], p= 0.004) and survival (HR = 0.975, CI [0.958, 0.993], p= 0.005) in RT treated patients. There was no significant relationship between physical RT dose or sham-GARD and survival or recurrence in any group, or in the pooled analysis. The interaction test revealed the effect of GARD on survival depends on whether or not that patient received RT (Wald statistic: p=0.026), as is the effect of GARD on first recurrence for all but those patients treated to the lowest GARD (for patients with GARD > 19.2Gy, Wald statistic: p=0.04).Conclusions Biologic effect, as quantified by GARD, is significantly associated with recurrence and survival in a continuous manner in RT treated patients, and physical RT dose is not. We propose that genomics should be integrated into radiation dosing decisions, using a GARD-based framework as the new paradigm for personalizing RT treatment.Competing Interest StatementJGS, SAE and JFTR hold IP on RSI, GARD and RxRSI, in addition to equity in Cvergenx, a company which seeks to commercialize these methods.Funding StatementNo funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is a retrospective analysis of published data, information on IRB approvals are contained in cited publications.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are published previously in this pooled analysis. The code (and data) are available on github. https://github.com/gsedor/GARD_Meta-Analysis